» Articles » PMID: 23492839

Mutation Analysis of TP53 Tumor Suppressor Gene in Colorectal Cancer in Patients from Iran (Kerman Province)

Overview
Specialty General Medicine
Date 2013 Mar 16
PMID 23492839
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: P53 is an important tumor suppressor, which is mutated in later stages of many cancers and leads to resistance to chemotherapy. The aim of this study was to reveal mutations of TP53 in colorectal cancer in Kerman province.

Materials And Methods: A total of Forty-three colon cancer specimens as paraffin block or fresh tissues, which passed stage IIIA, were selected. Three exons 5, 7 and 8 of P53 were amplified by PCR technique and sequenced directly.

Results: The results showed two deletions at codon 140 and 142 in one tumor sample. GAT→AAT mutation at codon 184, and CGG→TGG mutation at codon 248 were seen in some tumor samples. Some mutations were also observed in middle of intron 7 in some tumor or normal tissues.

Conclusion: Some of those patients with mutation in P53 gene had metastasis in other organs. Therefore, genetic test before chemotherapy is helpful for successful treatment.

Citing Articles

Association of MTHFR C677T variant genotype with serum folate and Vit B12 in Iranian patients with colorectal cancer or adenomatous polyps.

Ghorbani M, Azghandi M, Khayami R, Baharara J, Kerachian M BMC Med Genomics. 2021; 14(1):246.

PMID: 34645434 PMC: 8513199. DOI: 10.1186/s12920-021-01097-5.


PKM2 in carcinogenesis and oncotherapy.

He X, Du S, Lei T, Li X, Liu Y, Wang H Oncotarget. 2018; 8(66):110656-110670.

PMID: 29299177 PMC: 5746412. DOI: 10.18632/oncotarget.22529.


Rising rates of colorectal cancer among younger Iranians: is diet to blame?.

Hessami Arani S, Kerachian M Curr Oncol. 2017; 24(2):e131-e137.

PMID: 28490936 PMC: 5407876. DOI: 10.3747/co.23.3226.


Colorectal cancer in iran: molecular epidemiology and screening strategies.

Dolatkhah R, Somi M, Bonyadi M, Asvadi Kermani I, Farassati F, Dastgiri S J Cancer Epidemiol. 2015; 2015:643020.

PMID: 25685149 PMC: 4312646. DOI: 10.1155/2015/643020.

References
1.
Ambs S, BENNETT W, Merriam W, Ogunfusika M, Oser S, Harrington A . Relationship between p53 mutations and inducible nitric oxide synthase expression in human colorectal cancer. J Natl Cancer Inst. 1999; 91(1):86-8. DOI: 10.1093/jnci/91.1.86. View

2.
Compton C, Greene F . The staging of colorectal cancer: 2004 and beyond. CA Cancer J Clin. 2004; 54(6):295-308. DOI: 10.3322/canjclin.54.6.295. View

3.
Benhattar J, Cerottini J, Saraga E, Metthez G, Givel J . p53 mutations as a possible predictor of response to chemotherapy in metastatic colorectal carcinomas. Int J Cancer. 1996; 69(3):190-2. DOI: 10.1002/(SICI)1097-0215(19960621)69:3<190::AID-IJC7>3.0.CO;2-V. View

4.
Vousden K, Lane D . p53 in health and disease. Nat Rev Mol Cell Biol. 2007; 8(4):275-83. DOI: 10.1038/nrm2147. View

5.
Pineau P, Marchio A, Battiston C, Cordina E, Russo A, Terris B . Chromosome instability in human hepatocellular carcinoma depends on p53 status and aflatoxin exposure. Mutat Res. 2008; 653(1-2):6-13. DOI: 10.1016/j.mrgentox.2008.01.012. View